227 related articles for article (PubMed ID: 33128583)
1. CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy.
Hara A; Koyama-Nasu R; Takami M; Toyoda T; Aoki T; Ihara F; Kobayashi M; Hirono S; Matsutani T; Nakayama T; Iwadate Y; Motohashi S
Cancer Immunol Immunother; 2021 May; 70(5):1239-1254. PubMed ID: 33128583
[TBL] [Abstract][Full Text] [Related]
2. Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasms.
Bagnara D; Ibatici A; Corselli M; Sessarego N; Tenca C; De Santanna A; Mazzarello A; Daga A; Corvò R; De Rossi G; Frassoni F; Ciccone E; Fais F
Haematologica; 2009 Jul; 94(7):967-74. PubMed ID: 19454494
[TBL] [Abstract][Full Text] [Related]
3. Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner.
Aoki T; Takami M; Takatani T; Motoyoshi K; Ishii A; Hara A; Toyoda T; Okada R; Hino M; Koyama-Nasu R; Kiuchi M; Hirahara K; Kimura MY; Nakayama T; Shimojo N; Motohashi S
Cancer Sci; 2020 Jul; 111(7):2223-2233. PubMed ID: 32324315
[TBL] [Abstract][Full Text] [Related]
4. Thymosin alpha1 enhanced cytotoxicity of iNKT cells against colon cancer via upregulating CD1d expression.
Ni C; Wu P; Wu X; Zhang T; Zhang T; Wang Z; Zhang S; Qiu F; Huang J
Cancer Lett; 2015 Jan; 356(2 Pt B):579-88. PubMed ID: 25304368
[TBL] [Abstract][Full Text] [Related]
5. Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy.
Wolf BJ; Choi JE; Exley MA
Front Immunol; 2018; 9():384. PubMed ID: 29559971
[TBL] [Abstract][Full Text] [Related]
6. Type II Natural Killer T Cells Contribute to Protection Against Systemic Methicillin-Resistant
Genardi S; Visvabharathy L; Cao L; Morgun E; Cui Y; Qi C; Chen YH; Gapin L; Berdyshev E; Wang CR
Front Immunol; 2020; 11():610010. PubMed ID: 33312179
[TBL] [Abstract][Full Text] [Related]
7. A Potent CD1d-binding Glycolipid for iNKT-Cell-based Therapy Against Human Breast Cancer.
Seki T; Liu J; Brutkiewicz RR; Tsuji M
Anticancer Res; 2019 Feb; 39(2):549-555. PubMed ID: 30711929
[TBL] [Abstract][Full Text] [Related]
8. Human dendritic cells derived from embryonic stem cells stably modified with CD1d efficiently stimulate antitumor invariant natural killer T cell response.
Zeng J; Wang S
Stem Cells Transl Med; 2014 Jan; 3(1):69-80. PubMed ID: 24292792
[TBL] [Abstract][Full Text] [Related]
9. Utilization of invariant natural killer T cells for gastric cancer treatment.
Xu Q; Li J; Zhang N; Zhang L; Qian R
Future Oncol; 2018 Aug; 14(20):2053-2066. PubMed ID: 30051730
[TBL] [Abstract][Full Text] [Related]
10. Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells.
Liu D; Song L; Brawley VS; Robison N; Wei J; Gao X; Tian G; Margol A; Ahmed N; Asgharzadeh S; Metelitsa LS
Clin Immunol; 2013 Oct; 149(1):55-64. PubMed ID: 23891738
[TBL] [Abstract][Full Text] [Related]
11. Retinoic acid induction of CD1d expression primes chronic lymphocytic leukemia B cells for killing by CD8
Ghnewa YG; O'Reilly VP; Vandenberghe E; Browne PV; McElligott AM; Doherty DG
Clin Immunol; 2017 Oct; 183():91-98. PubMed ID: 28780376
[TBL] [Abstract][Full Text] [Related]
12. Functions of CD1d-Restricted Invariant Natural Killer T Cells in Antimicrobial Immunity and Potential Applications for Infection Control.
Kinjo Y; Takatsuka S; Kitano N; Kawakubo S; Abe M; Ueno K; Miyazaki Y
Front Immunol; 2018; 9():1266. PubMed ID: 29928278
[TBL] [Abstract][Full Text] [Related]
13. Combination of NKT14m and Low Dose IL-12 Promotes Invariant Natural Killer T Cell IFN-γ Production and Tumor Control.
Guan P; Schaub R; Nichols KE; Das R
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708464
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells.
Webb TJ; Bieler JG; Schneck JP; Oelke M
J Immunol Methods; 2009 Jul; 346(1-2):38-44. PubMed ID: 19446558
[TBL] [Abstract][Full Text] [Related]
15. CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis.
Hix LM; Shi YH; Brutkiewicz RR; Stein PL; Wang CR; Zhang M
PLoS One; 2011; 6(6):e20702. PubMed ID: 21695190
[TBL] [Abstract][Full Text] [Related]
16. Exploiting the CD1d-iNKT cell axis for potentiation of DC-based cancer vaccines.
Lameris R; Schneiders FL; de Gruijl TD; van der Vliet HJ
Methods Mol Biol; 2014; 1139():155-65. PubMed ID: 24619678
[TBL] [Abstract][Full Text] [Related]
17. Fas/FasL interaction mediates imbalanced cytokine/cytotoxicity responses of iNKT cells against Jurkat cells.
Dou R; Hong Z; Tan X; Hu F; Ding Y; Wang W; Liang Z; Zhong R; Wu X; Weng X
Mol Immunol; 2018 Jul; 99():145-153. PubMed ID: 29783159
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma.
Hunn MK; Farrand KJ; Broadley KW; Weinkove R; Ferguson P; Miller RJ; Field CS; Petersen T; McConnell MJ; Hermans IF
Clin Cancer Res; 2012 Dec; 18(23):6446-59. PubMed ID: 23147997
[TBL] [Abstract][Full Text] [Related]
19. The tumor antigen N-glycolyl-GM3 is a human CD1d ligand capable of mediating B cell and natural killer T cell interaction.
Gentilini MV; Pérez ME; Fernández PM; Fainboim L; Arana E
Cancer Immunol Immunother; 2016 May; 65(5):551-62. PubMed ID: 26969612
[TBL] [Abstract][Full Text] [Related]
20. CD252 regulates mast cell mediated, CD1d-restricted NKT-cell activation in mice.
Gonzalez Roldan N; Orinska Z; Ewers H; Bulfone-Paus S
Eur J Immunol; 2016 Feb; 46(2):432-9. PubMed ID: 26564814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
